MAP2K7 and melanoma: For this purpose, we employed the (i) MEK inhibitor trametinib and (ii) vemurafenib plus cobimetinib, an FDA- and EMA-approved BRAF/MEK inhibitor combination for BRAFV600-mutated melanoma.